Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

BACKGROUND: Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the first-in-human phase I study of BI 853520, a novel, potent, highly selective FAK inhibitor. OBJECTIVE: Our objectives were to identify the maxim...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407740/
https://www.ncbi.nlm.nih.gov/pubmed/30756308
http://dx.doi.org/10.1007/s11523-018-00617-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407740/
https://www.ncbi.nlm.nih.gov/pubmed/30756308
http://dx.doi.org/10.1007/s11523-018-00617-1

Ejemplares similares